The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study
Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking...
Saved in:
| Published in | Biopharmaceutics & drug disposition Vol. 42; no. 6; pp. 252 - 262 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.06.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100–150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required.
CYP 2C19 based dose optimisation is required throughout gestation. Both EM and UM phenotypes require doses of 100–150 mg daily throughout gestation, where PM require 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3. |
|---|---|
| AbstractList | Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100–150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required. Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100-150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required.Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100-150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required. Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100–150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required. CYP 2C19 based dose optimisation is required throughout gestation. Both EM and UM phenotypes require doses of 100–150 mg daily throughout gestation, where PM require 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3. |
| Author | Macfarlane, Hannah Badhan, Raj K. S. Almurjan, Aminah |
| Author_xml | – sequence: 1 givenname: Aminah surname: Almurjan fullname: Almurjan, Aminah organization: Aston University – sequence: 2 givenname: Hannah surname: Macfarlane fullname: Macfarlane, Hannah organization: Aston University – sequence: 3 givenname: Raj K. S. orcidid: 0000-0002-0904-9324 surname: Badhan fullname: Badhan, Raj K. S. email: r.k.s.badhan@aston.ac.uk organization: Aston University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33851424$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kcluFDEQhi0URCYDEk-ALHHh0oOX7p5ubmHCJkWCQ5DgZLm9zHhw240X0OTJ8ni4MwlICC5lueqrql_1n4ET550C4ClGK4wQeTlIuSJk3T0AC4z6vkId_nICFgjXpCppcgrOYtwjhFqM8SNwSmnXlFq9ADdXOwX5NFkjeDLeQa_hFJQwcf5IH43bQuNgKliOai5HFVLg1jhVssHn7c7nNDdtHXfiALUPcPIlcCdhtoUNfDISjirxwVtzrQLcfP0EyQb3MOZhr0SKr-A5_GFCytxCUWYXORamYEqcdjyMXPhvZWMyIsKYsjw8Bg81t1E9uXuX4PPbN1eb99Xlx3cfNueXlaAd7SrZaz2sG46HruOtxFIOLSZNo4TsB4R1R2tea43XXHQIt1hwUjdY4bqmrRY9oUvw4jh3Cv57VjGx0UShrOVO-RwZaTBZk56WhiV4_he69zm4oq5QRU05OaWFenZH5WFUkk3BjDwc2L0nBVgdARF8jEFpJky6Naec0liGEZtNZ8V0Npv-R-LvhvuZ_0CrI_rTWHX4L8deX1zc8r8AL9C9Yg |
| CitedBy_id | crossref_primary_10_3389_fphar_2022_833217 crossref_primary_10_1016_j_jchromb_2023_123827 crossref_primary_10_1111_bcp_15826 crossref_primary_10_14412_2074_2711_2023_5_1_94_101 crossref_primary_10_3390_pharmaceutics15020556 crossref_primary_10_3390_metabo12121281 |
| Cites_doi | 10.1002/j.1875-9114.1992.tb04505.x 10.2165/11592640-000000000-00000 10.1111/acps.12042 10.1111/bcp.12685 10.1016/j.jpsychores.2010.07.008 10.1111/bcpt.12938 10.2165/00003088-200645100-00005 10.1055/s-0043-116492 10.1002/bdra.20773 10.1017/S0033291709992194 10.1002/cpt.770 10.1124/dmd.109.026609 10.1002/psp4.12110 10.2165/00003088-199700321-00004 10.1002/cpt.147 10.1007/BF00613820 10.1111/bcp.13565 10.1016/S1570-0232(02)00027-2 10.1016/j.jsbmb.2008.03.027 10.1038/s41386-019-0554-x 10.1016/j.xphs.2018.10.056 10.1080/15287390490273550 10.1080/17425255.2020.1750598 10.1097/JCP.0b013e3182490eaf 10.1124/dmd.114.062596 10.1136/eb-2016-102373 10.1016/S0009-9236(97)90118-1 10.1017/S1092852914000510 10.1002/bdd.2081 10.2471/BLT.11.091850 10.1192/bjp.150.6.782 10.1097/00002030-200305230-00011 10.1136/bmj.i1547 10.1038/s41540-020-00157-3 10.4088/PCC.v03n0404 10.1080/00498250701744633 10.1002/psp4.12274 10.1007/s00228-003-0651-x 10.1007/BF01243351 10.1111/j.1365-2125.1991.tb05594.x 10.1034/j.1399-5618.2002.01195.x 10.1016/j.ajog.2004.08.030 10.2165/11318050-000000000-00000 10.1007/s10928-020-09698-w 10.1016/S0029-7844(98)00444-X 10.2165/11597440-000000000-00000 10.2174/138920012800840374 10.1002/rcm.2610 10.1097/JCP.0b013e31818d2048 10.4088/JCP.v69n0419 10.1002/(SICI)1520-6394(2000)11:2<51::AID-DA1>3.0.CO;2-R 10.1007/s00228-003-0652-9 10.1016/j.bcp.2012.03.016 10.1371/journal.pone.0181082 10.1136/bmjopen-2016-013372 10.1111/j.1553-2712.1996.tb03400.x 10.1038/clpt.1985.114 10.1002/bdrb.20144 10.1111/j.1471-0528.2007.01387.x 10.1177/0269881117699361 10.1124/dmd.104.002428 10.1111/jphp.13281 10.1592/phco.22.12.1001.33603 10.1002/hup.502 10.1124/dmd.112.050245 10.1186/s12884-018-1825-y 10.1586/14737175.7.2.107 10.1007/s00737-015-0524-1 10.1177/009127000004000108 10.3390/ijms20102370 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd. 2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd. – notice: 2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd. |
| DBID | 24P AAYXX CITATION NPM 7QP 7QR 7TK 7U9 8FD FR3 H94 K9. P64 7X8 |
| DOI | 10.1002/bdd.2278 |
| DatabaseName | Wiley Online Library Open Access (WRLC) CrossRef PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed Virology and AIDS Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1099-081X |
| EndPage | 262 |
| ExternalDocumentID | 33851424 10_1002_bdd_2278 BDD2278 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Kuwait University |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23N 24P 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GWYGA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E V8K VH1 W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWP WXI WXSBR XG1 XPP XV2 YCJ ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7QP 7QR 7TK 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 7X8 |
| ID | FETCH-LOGICAL-c3838-d9ffb75a1b88a6d1ddb61255ecd9b01f834a4ff17ac80161ca2451e14436fc923 |
| IEDL.DBID | DR2 |
| ISSN | 0142-2782 1099-081X |
| IngestDate | Fri Jul 11 00:43:03 EDT 2025 Fri Jul 25 12:26:47 EDT 2025 Wed Feb 19 02:29:24 EST 2025 Tue Jul 01 03:35:38 EDT 2025 Thu Apr 24 23:04:16 EDT 2025 Wed Jan 22 16:30:32 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | phenotype PBPK pharmacokinetics pregnancy sertraline |
| Language | English |
| License | Attribution 2021 The Authors. Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3838-d9ffb75a1b88a6d1ddb61255ecd9b01f834a4ff17ac80161ca2451e14436fc923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0904-9324 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbdd.2278 |
| PMID | 33851424 |
| PQID | 2538351433 |
| PQPubID | 966330 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2512729344 proquest_journals_2538351433 pubmed_primary_33851424 crossref_citationtrail_10_1002_bdd_2278 crossref_primary_10_1002_bdd_2278 wiley_primary_10_1002_bdd_2278_BDD2278 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2021 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Bognor Regis |
| PublicationTitle | Biopharmaceutics & drug disposition |
| PublicationTitleAlternate | Biopharm Drug Dispos |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2017; 7 2018; 122 2013; 127 2004; 67 2008; 38 2014; 24e 2020; 16 2003; 59 2003; 17 2018; 84 2003; 18 2015; 80 2012; 13 1992; 12 2001; 03 2009; 48 2012; 51 2018; 7 1987; 150 2020; 6 2017; 31 2006; 20 2009; 92 2019; 20 2017; 38 2011; 70 2000; 11 2015; 43 2008; 28 2008; 69 2020; 47 2007; 7 2016; 352 2020; 45 1999; 93 2008; 110 1996; 3 1983; 24 2005; 33 2005; 192 1997; 62 2016; 19 2012 1991; 31 2015; 98 2013; 41 2018; 103 2005; 119 2008 2002; 4 2019; 108 2012; 32 2010; 40 2007; 114 2016; 5 2018; 18 2012; 90 2006; 45 1997; 32 2011; 91 2020; 72 2015; 20 1986; 67 2002; 22 2011; 50 2017; 12 2000; 40 2018; 51 2002; 769 2008; 83 1985; 37 2009; 37 2012; 84 e_1_2_7_5_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_60_1 e_1_2_7_17_1 e_1_2_7_62_1 e_1_2_7_41_1 e_1_2_7_64_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_66_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 Gaynes B. N. (e_1_2_7_21_1) 2005; 119 e_1_2_7_73_1 e_1_2_7_50_1 e_1_2_7_71_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_35_1 e_1_2_7_56_1 e_1_2_7_37_1 e_1_2_7_58_1 e_1_2_7_39_1 World Health Organization (e_1_2_7_75_1) 2008 e_1_2_7_6_1 e_1_2_7_4_1 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_61_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_63_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_65_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_67_1 Niyomnaitham S. (e_1_2_7_48_1) 2009; 92 e_1_2_7_69_1 e_1_2_7_27_1 e_1_2_7_29_1 e_1_2_7_72_1 Cunningham F. (e_1_2_7_15_1) 2014 e_1_2_7_51_1 e_1_2_7_70_1 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_76_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_55_1 e_1_2_7_74_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_57_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_59_1 e_1_2_7_38_1 U.S. Food and Drug Administration (e_1_2_7_68_1) 2012 |
| References_xml | – volume: 122 start-page: 501 issue: 5 year: 2018 end-page: 511 article-title: Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers publication-title: Basic and Clinical Pharmacology and Toxicology – volume: 119 start-page: 1 year: 2005 end-page: 8 article-title: Perinatal depression: Prevalence, screening accuracy, and screening outcomes publication-title: Evidence Report ‐ Technology Assessment – volume: 18 start-page: 385 issue: 5 year: 2003 end-page: 388 article-title: Long‐term efficacy and therapeutic drug monitoring of sertraline in major depression publication-title: Human Psychopharmacology: Clinical and Experimental – volume: 6 start-page: 36 issue: 1 year: 2020 article-title: Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy publication-title: Npj Syst Biol Appl – volume: 19 start-page: 187 issue: 1 year: 2016 end-page: 191 article-title: Mental health care use in relation to depressive symptoms among pregnant women in the USA publication-title: Arch Womens Ment Health – volume: 108 start-page: 661 issue: 1 year: 2019 end-page: 673 article-title: Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of zika virus infection publication-title: Journal of Pharmaceutical Sciences – volume: 67 start-page: 297 issue: 4 year: 2004 end-page: 329 article-title: Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents publication-title: Journal of Toxicology and Environmental Health, Part A – volume: 110 start-page: 138 issue: 1–2 year: 2008 end-page: 143 article-title: Estetrol: a unique steroid in human pregnancy publication-title: The Journal of Steroid Biochemistry and Molecular Biology – volume: 98 start-page: 127 issue: 2 year: 2015 end-page: 134 article-title: Clinical Pharmacogenetics implementation Consortium (CPIC) guideline forCYP2D6andCYP2C19Genotypes and dosing of selective serotonin reuptake inhibitors publication-title: Clinical Pharmacology & Therapeutics – volume: 4 start-page: 323 issue: 5 year: 2002 end-page: 327 article-title: A clinical monitoring form for mood disorders publication-title: Bipolar Disorders – volume: 45 start-page: 570 issue: 3 year: 2020 end-page: 576 article-title: Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients publication-title: Neuropsychopharmacol. – volume: 40 start-page: 1723 issue: 10 year: 2010 end-page: 1733 article-title: Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data publication-title: Psychological Medicine – volume: 7 issue: 1 year: 2017 article-title: Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the quebec pregnancy cohort publication-title: BMJ open – volume: 114 start-page: 1055 issue: 9 year: 2007 end-page: 1064 article-title: Prevalence and predictors of antidepressant use in a cohort of pregnant women publication-title: BJOG: An International Journal of Obstetrics and Gynaecology – volume: 38 start-page: 62 issue: 1 year: 2008 end-page: 75 article-title: Regulation of UDP‐glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination publication-title: Xenobiotica – volume: 11 start-page: 51 issue: 2 year: 2000 end-page: 57 article-title: Dose of selective serotonin uptake inhibitors across pregnancy: Clinical implications publication-title: Depression and Anxiety – volume: 92 start-page: 1229 issue: 9 year: 2009 end-page: 1233 article-title: Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers publication-title: Medical Journal of the Medical Association of Thailand – volume: 91 start-page: 142 issue: 3 year: 2011 end-page: 152 article-title: Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy publication-title: Birth Defects Research Part A: Clinical and Molecular Teratology – year: 2008 – volume: 69 start-page: 652 issue: 4 year: 2008 end-page: 658 article-title: Changes in antidepressant metabolism and dosing across pregnancy and early postpartum publication-title: Journal of Clinical Psychiatry – volume: 80 start-page: 1031 issue: 5 year: 2015 end-page: 1041 article-title: Physiologically‐based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women publication-title: British Journal of Clinical Pharmacology – volume: 48 start-page: 677 issue: 10 year: 2009 end-page: 683 article-title: Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy publication-title: Clinical Pharmacokinetics – volume: 72 start-page: 1049 issue: 8 year: 2020 end-page: 1060 article-title: Precision dosing‐based optimization of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolizers: A virtual clinical trial pharmacokinetics study publication-title: Journal of Pharmacy and Pharmacology – volume: 59 start-page: 545 issue: 7 year: 2003 end-page: 552 article-title: The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria publication-title: European Journal of Clinical Pharmacology – volume: 20 start-page: 2483 year: 2006 end-page: 2489 article-title: Development and validation of a liquid chromatographic/tandem mass spectrometric method for the determination of sertraline in human plasma publication-title: Rapid Communications in Mass Spectrometry – volume: 38 start-page: 426 issue: 7 year: 2017 end-page: 438 article-title: Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations publication-title: Biopharmaceutics & Drug Disposition – volume: 47 start-page: 319 issue: 4 year: 2020 end-page: 340 article-title: Drug dosing during pregnancy‐opportunities for physiologically based pharmacokinetic models publication-title: Journal of Pharmacokinetics and Pharmacodynamics – volume: 84 start-page: 1335 issue: 6 year: 2018 end-page: 1345 article-title: Physiologically‐based pharmacokinetic modeling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data publication-title: British Journal of Clinical Pharmacology – volume: 37 start-page: 1841 issue: 9 year: 2009 end-page: 1847 article-title: Up‐regulation of UDP‐glucuronosyltransferase (UGT) 1A4 by 17β‐estradiol: A potential mechanism of increased lamotrigine elimination in pregnancy publication-title: Drug Metabolism & Disposition – volume: 83 start-page: 68 issue: 1 year: 2008 end-page: 76 article-title: Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population‐based health data publication-title: Birth Defects Research B – volume: 17 start-page: 1195 issue: 8 year: 2003 end-page: 1199 article-title: Pharmacokinetics of nelfinavir and indinavir in HIV‐1‐infected pregnant women publication-title: Aids – volume: 93 start-page: 858 issue: 5 year: 1999 end-page: 868 article-title: Pharmacokinetics during pregnancy: Evidence‐based maternal dose formulation publication-title: Obstetrics & Gynecology – volume: 62 start-page: 400 issue: 4 year: 1997 end-page: 407 article-title: Induction of CYP2D6 in pregnancy publication-title: Clinical Pharmacology & Therapeutics – volume: 769 start-page: 333 issue: 2 year: 2002 end-page: 339 article-title: Rapid and sensitive determination of sertraline in human plasma using gas chromatography‐mass spectrometry publication-title: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences – volume: 32 start-page: 186 issue: 2 year: 2012 end-page: 194 article-title: Pregnancy outcome after exposure to antidepressants and the role of maternal depression publication-title: Journal of clinical psychopharmacology – volume: 67 start-page: 241 issue: 3–4 year: 1986 end-page: 266 article-title: On central effects of serotonin re‐uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine publication-title: Journal of Neural Transmission – volume: 90 start-page: 139 issue: 2 year: 2012 end-page: 149H article-title: Prevalence and determinants of common perinatal mental disorders in women in low‐ and lower‐middle‐income countries: A systematic review publication-title: Bulletin of the World Health Organization – volume: 40 start-page: 58 issue: 1 year: 2000 end-page: 66 article-title: CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations publication-title: The Journal of Clinical Pharmacology – volume: 192 start-page: 633 issue: 2 year: 2005 end-page: 639 article-title: Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy publication-title: American Journal of Obstetrics and Gynecology – volume: 127 start-page: 94 issue: 2 year: 2013 end-page: 114 article-title: Antidepressant use in pregnancy: A critical review focused on risks and controversies publication-title: Acta Psychiatrica Scandinavica – volume: 37 start-page: 688 issue: 6 year: 1985 end-page: 692 article-title: Pregnancy‐induced increase in metoprolol metabolism publication-title: Clinical Pharmacology & Therapeutics – volume: 51 start-page: 365 issue: 6 year: 2012 end-page: 396 article-title: Anatomical, physiological and metabolic changes with gestational age during normal pregnancy publication-title: Clinical Pharmacokinetics – volume: 33 start-page: 262 issue: 2 year: 2005 end-page: 270 article-title: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study publication-title: Drug Metabolism & Disposition – volume: 41 start-page: 256 issue: 2 year: 2013 end-page: 262 article-title: Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? publication-title: Drug Metabolism & Disposition – volume: 31 start-page: 689 issue: 6 year: 1991 end-page: 692 article-title: The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study publication-title: British Journal of Clinical Pharmacology – volume: 43 start-page: 510 issue: 4 year: 2015 end-page: 522 article-title: Physiologically based pharmacokinetic modeling for sequential metabolism: Effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics publication-title: Drug Metabolism & Disposition – volume: 03 start-page: 168 year: 2001 end-page: 174 article-title: Steps following attainment of remission publication-title: Primary Care Companion to the Journal of Clinical Psychiatry – volume: 70 start-page: 385 issue: 4 year: 2011 end-page: 389 article-title: Validation of the edinburgh depression scale during pregnancy publication-title: Journal of Psychosomatic Research – volume: 24 start-page: 217 issue: 2 year: 1983 end-page: 220 article-title: Increased oral clearance of metoprolol in pregnancy publication-title: European Journal of Clinical Pharmacology – volume: 150 start-page: 782 year: 1987 end-page: 786 article-title: Detection of postnatal depression publication-title: British Journal of Psychiatry – volume: 13 start-page: 695 issue: 6 year: 2012 end-page: 720 article-title: Physiologically‐based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: Achievements and shortcomings publication-title: Cdm – volume: 18 start-page: 187 issue: 1 year: 2018 article-title: Antidepressant use during pregnancy and the risk of developing gestational hypertension: A retrospective cohort study publication-title: BMC Pregnancy and Childbirth – year: 2012 – volume: 51 start-page: 9 issue: 01/02 year: 2018 end-page: 62 article-title: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017 publication-title: Pharmacopsychiatry – volume: 84 start-page: 93 issue: 1 year: 2012 end-page: 103 article-title: Estradiol induces cytochrome P450 2B6 expression at high concentrations: Implication in estrogen‐mediated gene regulation in pregnancy publication-title: Biochemical Pharmacology – volume: 352 year: 2016 article-title: Depression in pregnancy publication-title: BMJ – volume: 50 start-page: 613 issue: 9 year: 2011 end-page: 623 article-title: Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants publication-title: Clinical Pharmacokinetics – volume: 12 issue: 7 year: 2017 article-title: Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition publication-title: PloS One – volume: 7 start-page: 103 issue: 2 year: 2018 end-page: 110 article-title: Drug dosing in pregnant women: Challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations publication-title: CPT: Pharmacometrics & Systems Pharmacology – volume: 24e year: 2014 – volume: 20 start-page: 2370 issue: 10 year: 2019 article-title: SSRIs and SNRIs (SRI) in pregnancy: Effects on the course of pregnancy and the offspring: How far are we from having all the answers? publication-title: Ijms – volume: 31 start-page: 519 issue: 5 year: 2017 end-page: 552 article-title: British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017 publication-title: Journal of Psychopharmacology – volume: 19 start-page: 122 issue: 4 year: 2016 article-title: Perinatal suicide associated with depression diagnosis and absence of active treatment in 15‐year UK national inquiry publication-title: Evidence‐Based Mental Health – volume: 28 start-page: 646 issue: 6 year: 2008 end-page: 653 article-title: Pharmacokinetics of sertraline across pregnancy and postpartum publication-title: Journal of Clinical Psychopharmacology – volume: 32 start-page: 22 issue: Suppl 1 year: 1997 end-page: 30 article-title: Pharmacokinetics of sertraline and its N‐demethyl metabolite in elderly and young male and female volunteers publication-title: Clinical Pharmacokinetics – volume: 22 start-page: 1001 issue: 8 year: 2002 end-page: 1006 article-title: CYP2D6 inhibition by selective serotonin reuptake inhibitors: Analysis of achievable steady‐state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6 publication-title: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy – volume: 16 start-page: 431 issue: 5 year: 2020 end-page: 440 article-title: The impact of pregnancy on the pharmacokinetics of antidepressants: A systematic critical review and meta‐analysis publication-title: Expert Opinion on Drug Metabolism and Toxicology – volume: 20 start-page: 11 issue: 1 year: 2015 end-page: 19 article-title: Detection and treatment rates for perinatal depression in a state Medicaid population publication-title: CNS Spectrums – volume: 103 start-page: 477 issue: 3 year: 2018 end-page: 484 article-title: Treatment with antipsychotics in pregnancy: Changes in drug disposition publication-title: Clinical Pharmacology & Therapeutics – volume: 7 start-page: 107 issue: 2 year: 2007 end-page: 120 article-title: Paroxetine: Current status in psychiatry publication-title: Expert Review of Neurotherapeutics – volume: 12 start-page: 174 issue: 3 year: 1992 end-page: 177 article-title: Oral nifedipine pharmacokinetics in pregnancy‐induced hypertension publication-title: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy – volume: 5 start-page: 505 issue: 10 year: 2016 end-page: 515 article-title: Quantitative prediction of drug‐drug interactions involving inhibitory metabolites in drug development: How can physiologically based pharmacokinetic modeling help? publication-title: CPT: Pharmacometrics & Systems Pharmacology – volume: 3 start-page: 132 issue: 2 year: 1996 end-page: 136 article-title: Sertraline overdose publication-title: Academic Emergency Medicine – volume: 45 start-page: 1013 issue: 10 year: 2006 end-page: 1034 article-title: Development and evaluation of a generic physiologically based pharmacokinetic model for children publication-title: Clinical Pharmacokinetics – volume: 59 start-page: 553 issue: 7 year: 2003 end-page: 557 article-title: Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil publication-title: European Journal of Clinical Pharmacology – ident: e_1_2_7_56_1 doi: 10.1002/j.1875-9114.1992.tb04505.x – ident: e_1_2_7_55_1 doi: 10.2165/11592640-000000000-00000 – ident: e_1_2_7_9_1 doi: 10.1111/acps.12042 – ident: e_1_2_7_16_1 doi: 10.1111/bcp.12685 – ident: e_1_2_7_7_1 doi: 10.1016/j.jpsychores.2010.07.008 – ident: e_1_2_7_61_1 doi: 10.1111/bcpt.12938 – ident: e_1_2_7_18_1 doi: 10.2165/00003088-200645100-00005 – ident: e_1_2_7_27_1 doi: 10.1055/s-0043-116492 – ident: e_1_2_7_13_1 doi: 10.1002/bdra.20773 – ident: e_1_2_7_58_1 doi: 10.1017/S0033291709992194 – ident: e_1_2_7_73_1 doi: 10.1002/cpt.770 – ident: e_1_2_7_11_1 doi: 10.1124/dmd.109.026609 – ident: e_1_2_7_66_1 doi: 10.1002/psp4.12110 – ident: e_1_2_7_59_1 doi: 10.2165/00003088-199700321-00004 – ident: e_1_2_7_26_1 doi: 10.1002/cpt.147 – ident: e_1_2_7_29_1 doi: 10.1007/BF00613820 – ident: e_1_2_7_25_1 doi: 10.1111/bcp.13565 – ident: e_1_2_7_37_1 doi: 10.1016/S1570-0232(02)00027-2 – ident: e_1_2_7_30_1 doi: 10.1016/j.jsbmb.2008.03.027 – ident: e_1_2_7_8_1 doi: 10.1038/s41386-019-0554-x – ident: e_1_2_7_52_1 doi: 10.1016/j.xphs.2018.10.056 – ident: e_1_2_7_24_1 doi: 10.1080/15287390490273550 – ident: e_1_2_7_63_1 doi: 10.1080/17425255.2020.1750598 – ident: e_1_2_7_49_1 doi: 10.1097/JCP.0b013e3182490eaf – ident: e_1_2_7_17_1 doi: 10.1124/dmd.114.062596 – ident: e_1_2_7_36_1 doi: 10.1136/eb-2016-102373 – ident: e_1_2_7_71_1 doi: 10.1016/S0009-9236(97)90118-1 – ident: e_1_2_7_22_1 doi: 10.1017/S1092852914000510 – ident: e_1_2_7_34_1 doi: 10.1002/bdd.2081 – ident: e_1_2_7_19_1 doi: 10.2471/BLT.11.091850 – ident: e_1_2_7_14_1 doi: 10.1192/bjp.150.6.782 – ident: e_1_2_7_39_1 doi: 10.1097/00002030-200305230-00011 – ident: e_1_2_7_70_1 doi: 10.1136/bmj.i1547 – ident: e_1_2_7_23_1 doi: 10.1038/s41540-020-00157-3 – ident: e_1_2_7_64_1 doi: 10.4088/PCC.v03n0404 – ident: e_1_2_7_33_1 doi: 10.1080/00498250701744633 – volume-title: Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology year: 2012 ident: e_1_2_7_68_1 – ident: e_1_2_7_35_1 doi: 10.1002/psp4.12274 – ident: e_1_2_7_47_1 doi: 10.1007/s00228-003-0651-x – ident: e_1_2_7_62_1 doi: 10.1007/BF01243351 – ident: e_1_2_7_72_1 doi: 10.1111/j.1365-2125.1991.tb05594.x – ident: e_1_2_7_60_1 doi: 10.1034/j.1399-5618.2002.01195.x – ident: e_1_2_7_67_1 doi: 10.1016/j.ajog.2004.08.030 – ident: e_1_2_7_69_1 doi: 10.2165/11318050-000000000-00000 – ident: e_1_2_7_2_1 doi: 10.1007/s10928-020-09698-w – ident: e_1_2_7_42_1 doi: 10.1016/S0029-7844(98)00444-X – ident: e_1_2_7_3_1 doi: 10.2165/11597440-000000000-00000 – ident: e_1_2_7_43_1 doi: 10.2174/138920012800840374 – volume-title: The global burden of disease: 2004 update year: 2008 ident: e_1_2_7_75_1 – ident: e_1_2_7_12_1 doi: 10.1002/rcm.2610 – ident: e_1_2_7_20_1 doi: 10.1097/JCP.0b013e31818d2048 – volume: 119 start-page: 1 year: 2005 ident: e_1_2_7_21_1 article-title: Perinatal depression: Prevalence, screening accuracy, and screening outcomes publication-title: Evidence Report ‐ Technology Assessment – ident: e_1_2_7_65_1 doi: 10.4088/JCP.v69n0419 – ident: e_1_2_7_31_1 doi: 10.1002/(SICI)1520-6394(2000)11:2<51::AID-DA1>3.0.CO;2-R – ident: e_1_2_7_46_1 doi: 10.1007/s00228-003-0652-9 – ident: e_1_2_7_38_1 doi: 10.1016/j.bcp.2012.03.016 – ident: e_1_2_7_74_1 doi: 10.1371/journal.pone.0181082 – ident: e_1_2_7_6_1 doi: 10.1136/bmjopen-2016-013372 – ident: e_1_2_7_41_1 doi: 10.1111/j.1553-2712.1996.tb03400.x – year: 2014 ident: e_1_2_7_15_1 – ident: e_1_2_7_28_1 doi: 10.1038/clpt.1985.114 – ident: e_1_2_7_51_1 doi: 10.1002/bdrb.20144 – ident: e_1_2_7_57_1 doi: 10.1111/j.1471-0528.2007.01387.x – ident: e_1_2_7_45_1 doi: 10.1177/0269881117699361 – volume: 92 start-page: 1229 issue: 9 year: 2009 ident: e_1_2_7_48_1 article-title: Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers publication-title: Medical Journal of the Medical Association of Thailand – ident: e_1_2_7_50_1 doi: 10.1124/dmd.104.002428 – ident: e_1_2_7_5_1 doi: 10.1111/jphp.13281 – ident: e_1_2_7_40_1 doi: 10.1592/phco.22.12.1001.33603 – ident: e_1_2_7_44_1 doi: 10.1002/hup.502 – ident: e_1_2_7_32_1 doi: 10.1124/dmd.112.050245 – ident: e_1_2_7_76_1 doi: 10.1186/s12884-018-1825-y – ident: e_1_2_7_54_1 doi: 10.1586/14737175.7.2.107 – ident: e_1_2_7_10_1 doi: 10.1007/s00737-015-0524-1 – ident: e_1_2_7_4_1 doi: 10.1177/009127000004000108 – ident: e_1_2_7_53_1 doi: 10.3390/ijms20102370 |
| SSID | ssj0006111 |
| Score | 2.3121474 |
| Snippet | Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 252 |
| SubjectTerms | Antidepressants Clinical trials Dosage Gestation PBPK Pharmacokinetics phenotype Phenotypes Pregnancy Sertraline Titration |
| Title | The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbdd.2278 https://www.ncbi.nlm.nih.gov/pubmed/33851424 https://www.proquest.com/docview/2538351433 https://www.proquest.com/docview/2512729344 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BT1x4P0JLNUgoXOo0u147G24lpaqQQBFqpSIO1r6Mogbbiu1K6S_j5zHjR0J5SIiLfdixdy3P7nwzu_MNY6_QwdEKDVmAuuECmY5VoHysg4hbZ9HCTUJJ-c4fPsan5_L9RXTRnaqkXJiWH2ITcKOZ0azXNMG1KQ-3pKHGuRHlceLyS0e1CA992jJHxZy3pQib7BMlet7ZsTjsH7xpiX6DlzfRamNuTu6xL_1A21Mml6O6MiN7_QuH4_99yX12t0OhcNSqzQN2y2cP2XDe0livD-Bsm5VVHsAQ5luC6_Uj9h2b4aedb8hTKFZdsR5wOYUfYJEBYkuoS0_NtOdPIZXMQ1cZKK8reugrEX6sAaEzFDledOagXhIXgC4WDr75CrV0ubj2K5h9noOY8SmUtaHoUfkGjuBqsaIMGOgzPKEpQwJFN-BL7JE-Ahoa3cfs_OTd2ew06CpABBY9ZxW4aZqaSaS5UUrHjjtnCJFF3rqpGfNUhVLLNOUTbRVhV6uFjLhHJzGMU4vY9QnbyfLMP2Pg5VhZ47DRoAw65ipG9Yw8t4YwrBuw1702JLajR6cqHcukJXYWCf6mhH7TgL3cSBYtJcgfZPZ6hUq6RaFMBBoXSpwIQ3zFphmnM-3R6MznNclwgf5OKOWAPW0VcdMJDjqixMQBGzbq9Nfek7fHx3R__q-Cu-yOoLM6TXRpj-1Uq9q_QLBVmX12W8j5fjO5fgCuESmJ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6VcoALlFcbKDBIKFzqNOtXNnAqKVWAtopQKhUJydqXUdRgW7FdKf1l_Dxm_EgoDwlxsQ879u7Ks55vZne-YewlOjhSoCFzUDeM48d94QgbSifg2mi0cAPPp3znk9NwfOZ_OA_ON9ibNhem5odYBdxoZVT_a1rgFJDeX7OGKmN6lMh5g92kgt6VP_VpzR0Vcl4XI6zyT4TbMs_23f32yeu26DeAeR2vVgbn6C770g61Pmdy0SsL1dNXv7A4_udcttidBojCQa0599iGTe6z7qRmsl7uwXSdmJXvQRcma47r5QP2HZvhp81vSGPIFk29HjApRSBglgDCSyhzS8207U9RlcRCUxwoLQt66CtxfiwB0TNkKV5kYqCcEx2AzGYGvtkCFXU-u7ILGH2egDviQ8hLRQGk_DUcwOVsQUkw0CZ5QlWJBLJmwBfYI00CKibdh-zs6N10NHaaIhCORudZOGYYx2oQSK6EkKHhxigCZYHVZqj6PBaeL_045gOpBcFXLV0_4Bb9RC-MNcLXR2wzSRO7w8D6faGVwUaFMuibixA1NLBcK4KxpsNeteoQ6YYhnQp1zKOa29mN8DNF9Jk67MVKMqtZQf4gs9tqVNT8F_LIRftCuROeh69YNeOKpm0amdi0JBnuosvj-X6HbdeauOoEBx1QbmKHdSt9-mvv0dvDQ7o__lfB5-zWeHpyHB2_P_34hN126ehOFWzaZZvForRPEXsV6lm1xn4AGQgszQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF5BkRAv3EegwCCh8FKnXnvtbHgrCVG5qgi1UhEP1l5GUYNtJTZS-sv4ecz4SCiHhHixH3bs3ZVnPd_M7nzD2HN0cJREQ-ahblhPpL70pIuVF3FjDVq4YSgo3_nDUXx4It6eRqftqUrKhWn4ITYBN1oZ9f-aFnhh0_0taai2dkB5nJfZFRH7kjR68nFLHRVz3tQirNNPZNARz_rBfvfkRVP0G768CFdrezO9wT53I22OmZwNqlIPzPkvJI7_N5Wb7HoLQ-Gg0Ztb7JLLbrP-rOGxXu_B8TYta7UHfZhtGa7Xd9h3bIaftr4hT6FYttV6wOYUf4B5BgguoVo5aqZNf4qpZA7a0kB5VdJDX4jxYw2InaHI8aIyC9WCyABUMbfw1ZWopov5uVvC-NMMgjEfwarSFD5avYQD-DZfUgoMdCmeUNchgaId8Bn2SJOAmkf3LjuZvj4eH3ptCQjPoOssPTtKUz2MFNdSqthyazVBssgZO9I-T2UolEhTPlRGEng1KhARd-glhnFqELzeYztZnrkHDJzwpdEWGzXKoGcuY9TPyHGjCcTaHnvRaUNiWn50KtOxSBpm5yDBz5TQZ-qxZxvJouEE-YPMbqdQSftXWCUBWhfKnAhDfMWmGdczbdKozOUVyfAAHZ5QiB673yjiphMcdESZiT3Wr9Xpr70nryYTuj_8V8Gn7OpsMk3evzl694hdC-jcTh1p2mU75bJyjxF4lfpJvcJ-AJroK4U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+application+of+precision+dosing+in+the+use+of+sertraline+throughout+pregnancy+for+poor+and+ultrarapid+metabolizer+CYP+2C19+subjects%3A+A+virtual+clinical+trial+pharmacokinetics+study&rft.jtitle=Biopharmaceutics+%26+drug+disposition&rft.au=Almurjan%2C+Aminah&rft.au=Macfarlane%2C+Hannah&rft.au=Badhan%2C+Raj+K+S&rft.date=2021-06-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0142-2782&rft.eissn=1099-081X&rft.volume=42&rft.issue=6&rft.spage=252&rft.epage=262&rft_id=info:doi/10.1002%2Fbdd.2278&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0142-2782&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0142-2782&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0142-2782&client=summon |